CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Kyverna Therapeutics, Inc. (KYTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Kyverna Therapeutics, Inc. (KYTX)

Biological Products, (No Diagnostic Substances) · market cap $440M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-04-15 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Kyverna Therapeutics (KYTX) is a clinical-stage cell therapy company focused on autoimmune diseases, with 129 employees and a ~$540M market cap at ~$8.89/share. Its lead program is KYV-101, an anti-CD19 CAR-T therapy being evaluated across Lupus Nephritis, Systemic Sclerosis, and Multiple Sclerosis, alongside a Phase 3 Lupus Nephritis trial and a Phase 3 Myasthenia Gravis program. The company's most acute near-term issue is a reported cash position of $32.2M with a runway of only ~2.3 months, creating severe financing risk ahead of multiple pending readouts.
The catalyst path
  • 2027-04-15 (est.)Phase 2 · KYV-101imp 7/10
  • 2027-06-15 (est.)Phase 2 · KYV101imp 7/10
  • 2027-09-15 (est.)Phase 3 · KYV-101imp 9/10
Pipeline
AssetPhaseIndication
KYV-101 anti-CD19 CAR-T cell therapyPhase 2Lupus Nephritis
Standard lymphodepletion regimenPhase 3Lupus Nephritis
Anti-CD20 mABPhase 2Multiple Sclerosis, Primary Progressive
KYV-101Phase 3Systemic Sclerosis
KYV101Phase 2Rheumatoid Arthritis
Price & technical context
3-month
-43.6%
6-month
-46.8%
12-month
-31.1%
52-wk range
$4.61–$11.25
vs 50-day MA
-18.8%
vs 200-day MA
-36.0%
Realized vol
88.7%
Max drawdown
-71.8%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for KYTX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.